Late Breaking Abstract - Long-term durability of ivacaftor (IVA) treatment benefit in people with cystic fibrosis (PwCF)
C. Merlo (Baltimore, United States), C. Scirica (Boston, United States), T. Thorat (Boston, United States), L. Mcgarry (Boston, United States), M. Dersarkissian (Los Angeles, United States), C. Nguyen (Los Angeles, United States), Y. Gu (Los Angeles, United States), A. Muthukumar (Los Angeles, United States), J. Healy (Boston, United States), M. Brookhart (Durham, United States), J. Rubin (Boston, United States)
Source: International Congress 2022 – Physiologic studies of respiratory diseases
Session: Physiologic studies of respiratory diseases
Session type: Thematic Poster
Number: 2765
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Merlo (Baltimore, United States), C. Scirica (Boston, United States), T. Thorat (Boston, United States), L. Mcgarry (Boston, United States), M. Dersarkissian (Los Angeles, United States), C. Nguyen (Los Angeles, United States), Y. Gu (Los Angeles, United States), A. Muthukumar (Los Angeles, United States), J. Healy (Boston, United States), M. Brookhart (Durham, United States), J. Rubin (Boston, United States). Late Breaking Abstract - Long-term durability of ivacaftor (IVA) treatment benefit in people with cystic fibrosis (PwCF). 2765
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|